Synonym
PQCA; MSD-M1PAM; MSDM1PAM; MSD M1PAM
IUPAC/Chemical Name
1-((4-cyano-4-(pyridin-2-yl)piperidin-1-yl)methyl)-4-oxo-4H-quinolizine-3-carboxylic acid
InChi Key
RJTJRVASUFIDQM-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H20N4O3/c23-15-22(19-6-1-3-9-24-19)7-11-25(12-8-22)14-16-13-17(21(28)29)20(27)26-10-4-2-5-18(16)26/h1-6,9-10,13H,7-8,11-12,14H2,(H,28,29)
SMILES Code
O=C(C1=CC(CN2CCC(C3=NC=CC=C3)(C#N)CC2)=C4C=CC=CN4C1=O)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
1144504-35-7 ( PQCA free);
1401512-98-8 ( PQCA sodium)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
388.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lange HS, Cannon CE, Drott JT, Kuduk SD, Uslaner JM. The M1 Muscarinic
Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of
Memory and Attention in Rhesus Monkeys. J Pharmacol Exp Ther. 2015
Dec;355(3):442-50. doi: 10.1124/jpet.115.226712. Epub 2015 Oct 7. PubMed PMID:
26446308.
2: Puri V, Wang X, Vardigan JD, Kuduk SD, Uslaner JM. The selective positive
allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory
deficits in the Tg2576 Alzheimer's disease mouse model. Behav Brain Res.
2015;287:96-9. doi: 10.1016/j.bbr.2015.03.029. Epub 2015 Mar 20. PubMed PMID:
25800972.
3: Vardigan JD, Cannon CE, Puri V, Dancho M, Koser A, Wittmann M, Kuduk SD,
Renger JJ, Uslaner JM. Improved cognition without adverse effects: novel M1
muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus
monkey. Psychopharmacology (Berl). 2015 Jun;232(11):1859-66. doi:
10.1007/s00213-014-3813-x. Epub 2014 Dec 10. PubMed PMID: 25491927.
4: Nickols HH, Conn PJ. Development of allosteric modulators of GPCRs for
treatment of CNS disorders. Neurobiol Dis. 2014 Jan;61:55-71. doi:
10.1016/j.nbd.2013.09.013. Epub 2013 Sep 27. Review. PubMed PMID: 24076101;
PubMed Central PMCID: PMC3875303.
5: Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, Pearson M,
Vivian JA, Chang RK, Ray WJ, Kuduk SD, Wittmann M. The muscarinic M1 receptor
positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus
macaque, and rhesus macaque. Psychopharmacology (Berl). 2013 Jan;225(1):21-30.
doi: 10.1007/s00213-012-2788-8. Epub 2012 Jul 24. PubMed PMID: 22825578.
